The USFDA has recently accepted the New Drug Application (NDA) submitted by Adams Respiratory Therapeutics, Inc. (Nasdaq: ARXT) for 600 mg and 1200 mg oral solid extended release guaifenesin combination products for the prescription treatment of cough.
The said NDA is now under formal review of the USFDA – representing the first prescription product in Adams' current portfolio of respiratory products.
Adams Respiratory Therapeutics, Inc. is a specialty pharmaceutical company focused on the late-stage development, commercialization and marketing of over-the-counter and prescription pharmaceuticals for the treatment of respiratory disorders.
Read the full press release.
Comment Preview